Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: monoclonal antibody-based therapeutics - Compugen

Drug Profile

Research programme: monoclonal antibody-based therapeutics - Compugen

Alternative Names: Antibody-based cancer immunotherapies - Compugen; Cancer immunotherapies - Compugen; CGEN 15027-targeted mAb; CGEN 15027-targeted monoclonal antibody; CGEN 15032-targeted immunotherapeutic; CGEN 15052-targeted mAb; CGEN 15052-targeted monoclonal antibody; CGEN 15137-targeted antibody; CGEN 15137/TIGIT; CGEN 671-targeted mAb; CGEN 671-targeted monoclonal antibody; CGEN XXXX; CGEN-15022-targeted mAb; CGEN-15022-targeted monoclonal antibody; CGEN-15049-targeted mAb; CGEN-15049-targeted monclonal antibody; CGEN-928-targeted mAb; CGEN-928-targeted monoclonal antibody; Immune checkpoint-targeted monoclonal antibodies - Compugen; Splice variant-targeted monoclonal antibody therapeutics - Compugen

Latest Information Update: 28 Sep 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Compugen
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; B7 antigen inhibitors; CD28 antigen inhibitors; Immunomodulators; Membrane protein inhibitors; T lymphocyte stimulants; TIGIT protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Cancer; Haematological malignancies; Malignant melanoma; Multiple myeloma; Solid tumours

Most Recent Events

  • 28 Sep 2023 No recent reports of development identified for preclinical development in Cancer in Israel (Parenteral)
  • 06 Aug 2019 Preclinical trials in Cancer in Israel (Parenteral) before August 2019 (Compugen pipeline, August 2019)
  • 28 Nov 2018 No recent reports of development identified for preclinical development in Solid-tumours in Israel (Parenteral)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top